abstract |
The present invention relates to novel 21-hydroxy-6,19-oxide progesterone (21OH-6OP) analogs, their use as anti-glucocorticoid substances for the prevention and / or treatment of diseases associated with glucocorticoid excess. In particular, the present invention provides a method of treating Cushing's syndrome, iatrogenic hypercortisolism, or depression, wherein X is S, SO, or SO 2 , and R is It is either H or OH. The use of a new 21-hydroxy-6,19-oxideprogesterone (21OH-6OP) analog represented by}. The present invention also relates to a method for producing a novel 21-hydroxy-6,19-oxideprogesterone (21OH-6OP) analog. |